Dana-Farber Cancer Institute

Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I HER2-positive breast cancer spent getting treatment compared with IV delivery, according to results of a prospective study.

More than one-fourth of adolescents and young adults with cancer who wished to die at home did not attain this goal, according to research published in JAMA Network Open.

Cannabidiol may reduce scan-related anxiety among women with advanced breast cancer, according to results of randomized phase 2 study results.

SAN DIEGO — Lauren E. Merz, MD, MSc, can still feel both the relief and anger two parents expressed during her first year of medical school at University of Michigan.

SAN DIEGO — In this video, Marlise R. Luskin, MD, MSCE, highlights updates from two groups evaluating blinatumomab and ponatinib for the treatment of acute lymphoblastic leukemia.

Glucarpidase significantly improved kidney function for patients who developed acute kidney injury from high-dose methotrexate, according to results of a large, multicenter observational study.

Despite tremendous progress in lung cancer treatment and survival the past few decades, one startling trend has emerged.

SAN ANTONIO — In this video, Judy Garber, MD, MPH, discusses the results of the OlympiA trial presented at San Antonio Breast Cancer Symposium.

SAN ANTONIO — The addition of palbociclib to standard care extended median PFS for patients with hormone receptor-positive, HER2-positive metastatic breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.

SAN ANTONIO — One year of adjuvant olaparib after standard treatment improved outcomes compared with placebo among patients with high-risk BRCA-mutated breast cancer, according to data presented at San Antonio Breast Cancer Symposium.